Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Liabilities (2016 - 2026)

Ocular Therapeutix has reported Total Liabilities over the past 14 years, most recently at $151.0 million for Q1 2026.

  • For Q1 2026, Total Liabilities rose 7.83% year-over-year to $151.0 million; the TTM value through Mar 2026 reached $151.0 million, up 7.83%, while the annual FY2025 figure was $153.7 million, 7.82% up from the prior year.
  • Total Liabilities for Q1 2026 was $151.0 million at Ocular Therapeutix, down from $153.7 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $160.9 million in Q4 2023 and troughed at $107.3 million in Q2 2022.
  • A 5-year average of $134.7 million and a median of $139.4 million in 2024 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: crashed 32.45% in 2022 and later soared 41.28% in 2023.
  • Year by year, Total Liabilities stood at $113.9 million in 2022, then soared by 41.28% to $160.9 million in 2023, then decreased by 11.4% to $142.6 million in 2024, then increased by 7.82% to $153.7 million in 2025, then decreased by 1.82% to $151.0 million in 2026.
  • Business Quant data shows Total Liabilities for OCUL at $151.0 million in Q1 2026, $153.7 million in Q4 2025, and $152.7 million in Q3 2025.